• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高 MAPK 活性在结直肠癌细胞祖细胞中的致癌作用,且与 RAS 突变无关而持续存在。

Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.

机构信息

Pathologisches Institut, Ludwig-Maximilians-Universität München, München, Germany.

German Cancer Consortium (DKTK), Heidelberg, Germany.

出版信息

Cancer Res. 2017 Apr 1;77(7):1763-1774. doi: 10.1158/0008-5472.CAN-16-2821. Epub 2017 Feb 15.

DOI:10.1158/0008-5472.CAN-16-2821
PMID:28202525
Abstract

About 40% of colorectal cancers have mutations in KRAS accompanied by downstream activation of MAPK signaling, which promotes tumor invasion and progression. Here, we report that MAPK signaling shows strong intratumoral heterogeneity and unexpectedly remains regulated in colorectal cancer irrespective of KRAS mutation status. Using primary colorectal cancer tissues, xenograft models, and MAPK reporter constructs, we showed that tumor cells with high MAPK activity resided specifically at the leading tumor edge, ceased to proliferate, underwent epithelial-mesenchymal transition (EMT), and expressed markers related to colon cancer stem cells. In KRAS-mutant colon cancer, regulation of MAPK signaling was preserved through remaining wild-type RAS isoforms. Moreover, using a lineage tracing strategy, we provide evidence that high MAPK activity marked a progenitor cell compartment of growth-fueling colon cancer cells Our results imply that differential MAPK signaling balances EMT, cancer stem cell potential, and tumor growth in colorectal cancer. .

摘要

大约 40%的结直肠癌存在 KRAS 突变伴下游 MAPK 信号通路的激活,这促进了肿瘤的侵袭和进展。在这里,我们报告称 MAPK 信号通路显示出很强的肿瘤内异质性,出人意料的是,无论 KRAS 突变状态如何,MAPK 信号通路仍受到调控。我们使用原发性结直肠癌组织、异种移植模型和 MAPK 报告基因构建体表明,具有高 MAPK 活性的肿瘤细胞特异性地位于肿瘤前沿,停止增殖,经历上皮-间充质转化(EMT),并表达与结肠癌细胞干相关的标志物。在 KRAS 突变的结肠癌中,MAPK 信号通路的调节通过剩余的野生型 RAS 同工型得以维持。此外,我们使用谱系追踪策略提供了证据表明,高 MAPK 活性标记了促进结肠癌细胞生长的祖细胞区室。我们的结果表明,不同的 MAPK 信号通路平衡了结直肠癌中的 EMT、癌症干细胞潜能和肿瘤生长。

相似文献

1
Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.高 MAPK 活性在结直肠癌细胞祖细胞中的致癌作用,且与 RAS 突变无关而持续存在。
Cancer Res. 2017 Apr 1;77(7):1763-1774. doi: 10.1158/0008-5472.CAN-16-2821. Epub 2017 Feb 15.
2
SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.SLC25A22 通过在细胞内合成天冬氨酸促进具有 KRAS 突变的结直肠癌细胞的增殖和存活,并促进小鼠异种移植肿瘤的进展。
Gastroenterology. 2016 Nov;151(5):945-960.e6. doi: 10.1053/j.gastro.2016.07.011. Epub 2016 Jul 21.
3
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.LY3009120是一种泛RAF抑制剂,在BRAF和KRAS突变的结直肠癌临床前模型中具有显著的抗肿瘤活性。
Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002.
4
STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways.STC2通过AKT-ERK信号通路促进结肠癌细胞的上皮-间质转化。
Oncotarget. 2016 Nov 1;7(44):71400-71416. doi: 10.18632/oncotarget.12147.
5
Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.挑战一种教条:结直肠癌中丝裂原活化蛋白激酶(MAPK)信号通路基因存在共突变。
Virchows Arch. 2016 Oct;469(4):459-64. doi: 10.1007/s00428-016-1991-0. Epub 2016 Jul 11.
6
Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model.高脂肪饮食可诱导结直肠癌细胞异种移植模型中的肿瘤进展和上皮间质转化。
J Nutr Biochem. 2012 Oct;23(10):1302-13. doi: 10.1016/j.jnutbio.2011.07.011. Epub 2012 Jan 4.
7
A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.一种突变型 KRAS 诱导因子 REG4 通过 Wnt/β-连环蛋白信号通路促进癌症干细胞特性。
Int J Cancer. 2020 May 15;146(10):2877-2890. doi: 10.1002/ijc.32728. Epub 2019 Nov 23.
8
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.针对 Wnt 通路和癌症干细胞的抗胃泌素人源化抗体作为治疗 K-RAS 突变型结直肠癌的潜在方法。
Clin Cancer Res. 2017 Sep 1;23(17):5267-5280. doi: 10.1158/1078-0432.CCR-17-0533. Epub 2017 Jun 9.
9
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.尼古丁通过 Gata6 依赖性去分化胰腺腺泡细胞促进 KRAS 诱导的胰腺癌的发生和进展。
Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.
10
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.上皮-间质转化定义了KRAS突变型肺癌中MEK抑制诱导的受体酪氨酸激酶信号的反馈激活。
Cancer Discov. 2016 Jul;6(7):754-69. doi: 10.1158/2159-8290.CD-15-1377. Epub 2016 May 6.

引用本文的文献

1
Multi-omics integration and machine learning uncover molecular basal-like subtype of pancreatic cancer and implicate A2ML1 in promoting tumor epithelial-mesenchymal transition.多组学整合与机器学习揭示胰腺癌分子基底样亚型并表明A2ML1在促进肿瘤上皮-间质转化中起作用。
J Transl Med. 2025 Jul 4;23(1):741. doi: 10.1186/s12967-025-06711-z.
2
Kallikrein-Related Peptidase 6 Contributes to Murine Intestinal Tumorigenesis Driven by a Mutant Gene.激肽释放酶相关肽酶6促进由突变基因驱动的小鼠肠道肿瘤发生。
Cancers (Basel). 2024 Nov 15;16(22):3842. doi: 10.3390/cancers16223842.
3
Integrative Transcriptomic and Single-Cell Protein Characterization of Colorectal Carcinoma Delineates Distinct Tumor Immune Microenvironments Associated with Overall Survival.
结直肠癌的综合转录组学和单细胞蛋白质特征描绘了与总生存期相关的不同肿瘤免疫微环境。
Res Sq. 2024 Jul 25:rs.3.rs-4751101. doi: 10.21203/rs.3.rs-4751101/v1.
4
Extracellular Signal-Regulated Kinases: One Pathway, Multiple Fates.细胞外信号调节激酶:一条通路,多种结局
Cancers (Basel). 2023 Dec 24;16(1):95. doi: 10.3390/cancers16010095.
5
Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?微卫星稳定或错配修复功能正常的转移性结直肠癌中的免疫检查点抑制剂:我们正在进入一个新时代吗?
Cancers (Basel). 2023 Oct 28;15(21):5189. doi: 10.3390/cancers15215189.
6
Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.组蛋白去乙酰化酶抑制剂 belinostat 与 Cu(II)形成复合物,可防止体外过早的代谢失活,并在体外和结肠癌的离体实验中表现出很强的抗癌活性。
Cell Oncol (Dordr). 2024 Apr;47(2):533-553. doi: 10.1007/s13402-023-00882-x. Epub 2023 Nov 7.
7
Peristalsis-Associated Mechanotransduction Drives Malignant Progression of Colorectal Cancer.蠕动相关的机械转导驱动结直肠癌的恶性进展。
Cell Mol Bioeng. 2023 Aug 11;16(4):261-281. doi: 10.1007/s12195-023-00776-w. eCollection 2023 Aug.
8
KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis.胃癌干细胞样细胞中的 KRAS 激活促进肿瘤血管生成和转移。
BMC Cancer. 2023 Jul 22;23(1):690. doi: 10.1186/s12885-023-11170-0.
9
Emerging roles of circ_NRIP1 in tumor development and cancer therapy (Review).环状核糖核酸NRIP1在肿瘤发生发展及癌症治疗中的新作用(综述)
Oncol Lett. 2023 Jun 8;26(1):321. doi: 10.3892/ol.2023.13907. eCollection 2023 Jul.
10
Inhibition of colon cancer K-Ras mutation reduces cancer cell proliferation but promotes stemness and inflammation RAS/ERK pathway.抑制结肠癌K-Ras突变可降低癌细胞增殖,但会促进干性及RAS/ERK通路炎症反应。
Front Pharmacol. 2022 Oct 28;13:996053. doi: 10.3389/fphar.2022.996053. eCollection 2022.